Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Haematol ; 152(6): 771-6, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21275961

ABSTRACT

In a phase-II multi-centre double-blinded trial, we evaluated haematological effects of oral hydroxycarbamide (HC) and magnesium (Mg) in patients with HbSC, aged 5-53 years old. Subjects were randomized to HC + placebo, Mg + placebo, HC + Mg, or placebo + placebo. The primary endpoint was the proportion of hyperdense red blood cells after 8 weeks. Thirty-six subjects were evaluable, but the study was terminated early because of slow enrollment. In the combined HC groups, mean cell volume and HbF were increased, but differences were not seen in hyperdense red cells or vaso-occlusive events. Mg had no effects. Further investigation of hydroxycarbamide as monotherapy in HbSC disease is warranted.


Subject(s)
Antisickling Agents/therapeutic use , Hemoglobin SC Disease/drug therapy , Hydroxyurea/therapeutic use , Magnesium/therapeutic use , Adolescent , Adult , Biomarkers/blood , Cell Adhesion/drug effects , Child , Child, Preschool , Double-Blind Method , Erythrocyte Indices/drug effects , Erythrocytes/drug effects , Erythrocytes/physiology , Female , Fetal Hemoglobin/metabolism , Hemoglobin SC Disease/blood , Humans , Hydroxyurea/adverse effects , Magnesium/adverse effects , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...